SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001126234-20-000032
Filing Date
2020-03-30
Accepted
2020-03-30 18:25:34
Documents
2
Period of Report
2020-03-23

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_158560711592838.html 3  
1 FORM 3 wf-form3_158560711592838.xml 3 1651
2 MCCRACKEN POA ex-24.htm EX-24 4364
  Complete submission text file 0001126234-20-000032.txt   7522
Mailing Address 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756
Business Address 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756 512-215-2630
LUMOS PHARMA, INC. (Issuer) CIK: 0001126234 (see all company filings)

IRS No.: 421491350 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NEXVET BIOPHARMA PLC NATL INST, FOSTERS AVENUE, MOUNT MERRION BLACKROCK L2 00000
Business Address
McCracken Joseph S (Reporting) CIK: 0001632454 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35342 | Film No.: 20758884